Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Seong Nam, Korea, Republic of Clinical Trials

A listing of Seong Nam, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

KM-819 for Patients With Parkinson's Disease

This first in human, single-center, randomized, placebo-controlled, double blind, sequential group Phase 1 study in healthy subjects will be conducted to evaluate the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) following the escalation of single and multiple doses of KM-819. The study will consist of 2 parts. In Part A, ...

Phase

0.0 miles

Learn More »

Study of the Safety Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in patients with advanced tumors.

Phase

0.0 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

0.0 miles

Learn More »

A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer

This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consists of 2 parts. Part 1 is a dose escalation and Part 2 is a dose expansion cohort. In Part 1, participants with evaluable non-small cell lung cancer (NSCLC) will ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.

Phase

0.0 miles

Learn More »

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

This is a Phase Ib, open-label, multicentre study of AZD9291 administered orally in combination with novel therapeutics (AZD6094 or selumetinib (AZD6244, ARRY142886)) to patients with EGFRm+ advanced NSCLC. The study has been designed to allow an investigation of the optimal combination dose and schedule whilst ensuring the safety of patients ...

Phase

0.0 miles

Learn More »

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF KRAS or NRAS Mutant Solid Cancers

This study evaluates the anti-tumor efficacy and safety of single agent HM95573 administered in patients with solid tumors harboring mutations in either BRAF, KRAS or NRAS gene.

Phase

0.0 miles

Learn More »

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

This is a Phase Ib, open label, multicenter dose escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral dosing of cobimetinib and HM95573 administered in combination in patients with histologically/cytologically confirmed, locally advanced, or metastatic solid tumors with RAS- or RAF-mutation for which standard therapies either do ...

Phase

0.0 miles

Learn More »

Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer

Pancreatic cancer is associated with an extremely poor prognosis, reflected by a 5-y survival probability of less than 5% when all stages are combined. At present, only approximately 10%-20% of patients are considered candidates for curative resection. The majority of patients (50%-60%) are present with metastatic disease, and substantial number ...

Phase

0.0 miles

Learn More »

Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea

Eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks before study drug administration. Subjects suitable for this study will be admitted to the Clinical Trial Center of CHA Bundang Medical Center on the day ...

Phase

0.0 miles

Learn More »